Tackling Cardiodiabesity: Innovative GLP-1 Strategies to manage Costs and Improve outcomes
Cardiodiabesity, the intersection of obesity, diabetes, and cardiovascular disease, is a significant health and financial burden in the U.S., contributing to over $838 billion in annual healthcare costs. As obesity rates rise, treatments like GLP-1s (glucagon-like peptide-1 agonists) are gaining popularity for managing both obesity and diabetes. However, the high demand for GLP-1s, driven in part by off-label use for weight loss, has led to supply shortages and soaring costs, straining healthcare plans.
To address these challenges a multi-faceted strategy is needed, one which will offer financial predictability and help manage the rising costs of GLP-1s through lifestyle modification support. Additionally, implementing targeted patient engagement, fraud prevention, and cost control measures for GLP-1s can make them more accessible and affordable for clinically appropriate patients improving long-term health outcomes.
Join our 60-minute interactive panel discussion as we analyze comprehensive approaches and innovative strategies to effectively mitigate the impact of cardiodiabesity.
Learning Objectives:
- Examining the rising demand for GLP-1 medications and strategies to control costs and ensure access.
- Leveraging data-driven strategies to tailor interventions, improve clinical outcomes, and reduce healthcare utilization.
- Exploring how combining GLP-1 treatment with lifestyle programs can improve outcomes and help manage costs.
Speakers:
- Michelle Leonard, Director, Supply Chain Product Sales Support, Express Scripts
- Janocqua Shaw, Director of Benefits and Leave Administration at The Save Mart Companies
- Melisa Spicer, Senior Director, Clinical Sales & Strategy, Evernorth
